A method for monitoring adverse drug reactions, an electronic device, and a storage medium

Abstract

The present invention provides a method for monitoring adverse drug reactions, including: at the current monitoring moment, obtaining a monitoring information set D within a set geographical area; for each piece of monitoring information, based on a preset adverse drug reaction reference table, determining whether it is adverse reaction data, and if so, storing the monitoring information in the adverse reaction information list corresponding to the current set geographical area; based on the adverse reaction information list corresponding to the current set geographical area, obtaining W target data sets; obtaining the monitored terminals that need to be warned based on the h-th target data set corresponding to the set geographical area within the h-th preset time period, and performing corresponding warning operations. The present invention can automatically monitor the adverse drug reactions of each monitored terminal in real time, improve the monitoring efficiency and monitoring effect, and ensure timely and effective monitoring.

Description

Technical Field

[0001] The present invention relates to the field of computer technology applications, and particularly to a method for monitoring adverse drug reactions, an electronic device, and a storage medium. Background Art

[0002] In some application scenarios, such as the field of drug monitoring, it is necessary to monitor adverse drug reactions in order to take corresponding intervention measures in a timely manner and minimize the harmful effects as much as possible. Currently, the monitoring of adverse drug reactions mainly relies on doctors themselves, and this monitoring method has problems such as poor monitoring timeliness and unsatisfactory effects. Summary of the Invention

[0003] In view of the above technical problems, the technical solution adopted by the present invention is as follows:

[0004] An embodiment of the present invention provides a method for monitoring adverse drug reactions, and the method includes the following steps:

[0005] S100, at the current monitoring moment, obtain a monitoring information set D = {D1, D2,..., D i ,..., D n} within a set geographical area, where D i is the monitoring information of the i-th monitored end within the set geographical area, and the value of i ranges from 1 to n, where n is the number of monitored ends; D i = {d i1 , d i2 ,..., d ij ,..., d ih(i)}, where d ij is the monitoring information of the j-th user of the i-th monitored end, and the value of j ranges from 1 to h(i), where h(i) is the number of users of the i-th monitored end; d ij = (U ij , A ij ), where U ij is the ID of the j-th user of the i-th monitored end; A ij is the characteristic information corresponding to U ij , and A ij = (M ij , L ij ), where M ij is the drug characteristic information corresponding to U ij , and L ij is the life characteristic information corresponding to U ij ; M ij = (M 1 ij , M 2 ij , ……, M rij , ……, M p ij ), M r ij is M ij the r-th drug feature in, where r ranges from 1 to p, and p is the number of drug features; L ij =(L 1 ij , L 2 ij , ……, L s ij , ……, L q ij ), L s ij is L ij the s-th life feature in, where s ranges from 1 to q, and q is the number of life features; the drug features at least include drug ID, drug origin, drug ingredients, and medication time.

[0006] S200. For d ij , based on a preset drug adverse reaction benchmark table, determine whether d ij is adverse reaction data. If so, store d ij in the adverse reaction information list corresponding to the currently set geographical area; the initial value of the adverse reaction information list corresponding to the currently set geographical area is a null value.

[0007] S300. Based on the adverse reaction information list corresponding to the currently set geographical area, obtain W target data sets; where the h-th target data set C h ={C h1 , C h2 , ……, C hr , ……, C hg}, C hr is the r-th sub-data set in C h , and C hr satisfies the following conditions: Each data in C hr has the same drug ID, drug origin, and drug ingredients, and the corresponding medication time is the h-th preset medication time and the corresponding life features of the corresponding life feature information are all the preset r-th life feature category; h ranges from 1 to W, and r ranges from 1 to g, where g is the number of preset life feature categories.

[0008] S400. Based on the h-th target data set corresponding to the set geographical area within the h-th preset time period, obtain the monitored end that needs to be warned and perform the corresponding warning operation; the target data set corresponding to the set geographical area within each preset time period includes the target data set corresponding to the currently set geographical area.

[0009] The present invention has at least the following beneficial effects:

[0010] The adverse drug reaction monitoring method provided by the embodiment of the present invention can automatically monitor the adverse drug reactions of each monitored end in real time, improve the monitoring efficiency and effect, and ensure timely and effective monitoring.

[0011] It should be understood that the content described in this part is not intended to identify the key or important features of the embodiments of the present invention, nor is it used to limit the scope of the present invention. Other features of the present invention will become easily understood through the following description. BRIEF DESCRIPTION OF THE DRAWINGS

[0012] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the following will briefly introduce the drawings required for the description of the embodiments. Obviously, the drawings in the following description are only some embodiments of the present invention. For those of ordinary skill in the art, without creative efforts, other drawings can be obtained based on these drawings.

[0013] Figure 1 It is a flowchart of the adverse drug reaction monitoring method provided by the embodiment of the present invention. DETAILED DESCRIPTION OF THE EMBODIMENTS

[0014] The following will clearly and completely describe the technical solutions in the embodiments of the present invention with reference to the drawings in the embodiments of the present invention. Obviously, the described embodiments are only some of the embodiments of the present invention, rather than all of them. Based on the embodiments of the present invention, all other embodiments obtained by those of ordinary skill in the art without creative efforts belong to the scope of protection of the present invention.

[0015] The embodiment of the present invention provides an adverse drug reaction monitoring method, as Figure 1 shown, which may include the following steps:

[0016] S100, at the current monitoring moment, obtain the monitoring information set D = {D1, D2,..., D i ,..., D n} within the set geographical area, where D i is the monitoring information of the i-th monitored end within the set geographical area, and the value of i ranges from 1 to n, where n is the number of monitored ends; D i = {d i1 , d i2 ,..., d ij ,..., d ih(i)}, where d ij is the monitoring information of the j-th user of the i-th monitored end, and the value of j ranges from 1 to h(i), where h(i) is the number of users of the i-th monitored end; dij =(U ij , A ij ), where U ij is the ID of the j-th user of the i-th monitored end; A ij is the characteristic information corresponding to U ij , and A ij =(M ij , L ij ), where M ij is the drug characteristic information corresponding to U ij , and L ij is the life characteristic information corresponding to U ij ; M ij =(M 1 ij , M 2 ij , ……, M r ij , ……, M p ij ), where M r ij is the r-th drug characteristic in M ij , and r ranges from 1 to p, where p is the number of drug characteristics; L ij =(L 1 ij , L 2 ij , ……, L s ij , ……, L q ij ), where L s ij is the s-th life characteristic in L ij , and s ranges from 1 to q, where q is the number of life characteristics; the drug characteristics at least include drug ID, drug origin, drug ingredients, and medication time.

[0017] In the embodiments of the present invention, the set geographical area can be set based on actual needs. For example, it can be a community, a hospital, a city, a province, etc. The monitored end can be a medical institution, such as a hospital, etc. The users of the monitored end can be patients.

[0018] In the embodiments of the present invention, the monitoring information set within the set geographical area can be obtained based on the corresponding monitoring center. The monitoring center and the corresponding monitored end can be nodes on the blockchain. An encryption / decryption unit can be set on each node and a private key can be deployed, and a smart contract can be deployed on the blockchain network.

[0019] In the embodiments of the present invention, obtaining monitoring data based on the blockchain can achieve the credibility of the identities of multi-medical institution data nodes and the evidence storage ability of data interaction messages between blockchains.

[0020] In the embodiments of the present invention, the encryption and decryption algorithms adopted by the encryption and decryption unit may be one or more of the following encryption and decryption algorithms: DES (Data Encryption Standard) data encryption standard algorithm, symmetric encryption AES, asymmetric encryption ECC, message digest MD5, or digital signature DSA. Preferably, the adopted encryption and decryption algorithm may be asymmetric encryption.

[0021] In the embodiments of the present invention, the ID of the user may be an identifier capable of characterizing the user's identity. For example, it may be the user's ID card number and medical insurance card number, or a combination of the user's name, ID card number, and medical insurance card number, etc. The ID of the monitored end may be a unique identifier capable of identifying the identity of the monitored end. The drug characteristic information may at least include the ID of the user, the ID of the monitored end, the name of the drug taken by the user, the place of origin of the drug taken by the user, i.e., the manufacturer of the drug, and the time when the user takes the drug. The vital characteristic information may at least include the symptoms of the user taking the drug and the user's physiological index data. The symptoms of taking the drug may include, for example, lethargy, drowsiness, etc. The physiological index data may include, for example, blood, blood pressure, imaging, body temperature, test and examination data, etc.

[0022] S200, for d ij , based on the preset drug adverse reaction benchmark table, judge whether d ij is adverse reaction data. If so, store d ij into the adverse reaction information list corresponding to the currently set geographical area; the initial value of the adverse reaction information list corresponding to the currently set geographical area is a null value.

[0023] In the embodiments of the present invention, the preset drug adverse reaction benchmark table may include the adverse reactions of different drugs and may be empirical data. Each row of the preset drug adverse reaction benchmark table may include the corresponding drug characteristic information and vital characteristic information.

[0024] In the embodiments of the present invention, it may be judged whether d ij is an adverse reaction event based on the preset drug adverse reaction prediction model. In an illustrative embodiment of the present invention, the preset drug adverse reaction prediction model may be a neural network model.

[0025] Further, S200 may specifically include:

[0026] S201, set the counting variable t = 1.

[0027] S202, obtain the similarity S ij between A t and B t ij ; if S t ij > S0, determine dij is adverse reaction data, and exits the current control program; otherwise, execute S203; B t is the t-th characteristic information in the preset drug adverse reaction reference table; S0 is the set similarity threshold.

[0028] In an embodiment of the present invention, the similarity can be the cosine similarity. S0 can be set according to actual needs. For example, S0 is 0.85 to 0.95.

[0029] In an embodiment of the present invention, the characteristic information in the preset drug adverse reaction reference table can be obtained based on actual drug tests.

[0030] S203, set t = t + 1. If t ≤ m, execute S202; otherwise, determine d ij is not adverse reaction data, and exits the current control program. Where m is the number of characteristic information in the preset drug adverse reaction reference table.

[0031] S300, based on the adverse reaction information list corresponding to the currently set geographical area, obtain W target data sets; where the h-th target data set C h ={C h1 , C h2 , ……, C hr , ……, C hg}, C hr is the r-th sub-data set in C h , and C hr satisfies the following conditions: Each data in C hr has the same drug ID, drug origin, and drug ingredients, and the corresponding medication time is the h-th preset medication time and the corresponding vital characteristic information corresponds to the vital characteristics of the preset r-th vital characteristic category; the value of h ranges from 1 to W, and the value of r ranges from 1 to g, where g is the number of preset vital characteristic categories.

[0032] In an illustrative embodiment of the present invention, the medication time may include a first preset medication time and a second preset medication time. In a preferred embodiment, the first preset medication time is within 2 hours after taking the medicine, that is, the medication time is 0 to 2 hours. The second preset medication time is within 24 hours after taking the medicine, that is, the medication time is 0 to 24 hours.

[0033] In an embodiment of the present invention, the vital characteristic categories may include the first type of vital characteristics to the third type of vital characteristics. Among them, the first type of vital characteristics is death, the second type of vital characteristics is at least one symptom such as asphyxia, shock, coma, cyanosis, etc., and the third type of vital characteristics is at least one of the following symptoms:

[0034] Symptom 1: Gastrointestinal discomfort, including nausea, vomiting, diarrhea, constipation, etc.

[0035] Symptom 2: Allergic reactions, including skin itching, redness, rashes, etc.

[0036] Symptom 3: Abnormalities in the central nervous system, including dizziness, headache, drowsiness, etc.

[0037] Symptom 4: Abnormalities in the blood system, including leukopenia, neutropenia, thrombocytopenia, etc.

[0038] Symptom 5: Abnormalities in liver and kidney functions, including fatigue, loss of appetite, decreased urine output, etc.

[0039] When the medication time is 2 times, it can be known that W = 2. When the vital sign category is 3 features, that is, g = 3, it can be known that each target data set can include 3 sub-data sets.

[0040] S400, obtain the monitored terminals that need to be warned based on the h-th target data set corresponding to the set geographical area within the h-th preset time period, and perform corresponding warning operations; the target data set corresponding to the set geographical area within each preset time period includes the target data set corresponding to the current set geographical area, that is, includes the existing target data set.

[0041] Further, in S400, obtain the monitored terminals that need to be warned based on at least the target data sets corresponding to the set geographical areas within the first preset time period and the second preset time period; wherein, the duration of the second preset time period is greater than the duration of the first preset time period.

[0042] In the embodiment of the present invention, the first preset time period and the second preset time period can be empirical values. In an illustrative embodiment, the duration of the first preset time period can be 1 day, and the duration of the second preset time period can be 3 days.

[0043] Further, S400 may specifically include:

[0044] S410, obtain the user quantity set G1 = {G11, G12,..., G1 r ,..., G1 g} corresponding to the target data set corresponding to the set geographical area within the first preset time period and the user quantity set G2 = {G21, G22,..., G2 r ,..., G2 g} corresponding to the target data set corresponding to the set geographical area within the second preset time period; G1 r is the number of users corresponding to the r-th sub-data set corresponding to the target data set corresponding to the set geographical area within the first preset time period, and G2 r is the number of users corresponding to the r-th sub-data set corresponding to the target data set corresponding to the set geographical area within the second preset time period.

[0045] Those skilled in the art know that the target data set corresponding to the first preset time period is the first target data set, and the target data set corresponding to the second preset time period is the second target data set.

[0046] S420, based on G1 r According to the first warning rule corresponding to the corresponding target data set, determine whether it is necessary to perform a warning operation on the corresponding monitored end. If so, perform the corresponding warning operation, and based on G2 r According to the second warning rule corresponding to the corresponding target data set, determine whether it is necessary to perform a warning operation on the corresponding monitored end. If so, perform the corresponding warning operation.

[0047] In the embodiment of the present invention, each warning rule includes at least a trigger condition and a warning level.

[0048] In the embodiment of the present invention, the trigger condition is a user number limit condition. For example, greater than, less than, equal to, greater than or equal to, less than or equal to how many people, etc. The warning level can be set according to actual needs. The warning level can be represented by different colors. For example, red, orange, yellow and other levels. In a schematic embodiment of the present invention, the first warning rule can be as shown in Table 2 below:

[0049] Table 2:

[0050]

[0051]

[0052] The second warning rule can be as shown in Table 3 below:

[0053] Table 3:

[0054]

[0055] Furthermore, S420 specifically includes:

[0056] If G1 or G2 meets the corresponding trigger condition, it is determined that it is necessary to perform a warning operation on the corresponding monitored end, and perform the corresponding warning operation based on the corresponding warning level.

[0057] In the embodiment of the present invention, the warning operation corresponding to each warning level is to mark the location of the corresponding monitored end as the corresponding color on the map corresponding to the set geographical area.

[0058] Further, in another embodiment of the present invention, the warning operation corresponding to each warning level may further include drawing a warning box above the location of the corresponding monitored end on the map corresponding to the set geographical area, and the corresponding warning content is set in the warning box. The specific warning content can be set according to actual needs. For example, it includes the ID of the corresponding geographical area, the number of warning users, etc.

[0059] Further, the warning operation corresponding to each warning level further includes: sending a warning message to the corresponding monitoring terminal. In the embodiment of the present invention, the monitoring terminal can be the communication devices of the corresponding units and personnel.

[0060] In the embodiment of the present invention, corresponding disposal can be carried out according to the specific situation of the warning signal, and it is judged whether it can enter the event library as an event that can be applied subsequently according to the level and content of the warning signal. For example, according to different levels of triggering warnings, relevant level of intervention measures can be taken. For example, for mild adverse reactions, relevant information can be fed back to medical institutions, and regulatory agencies can make records. For critical levels: triggering group drug adverse reactions and endangering the life safety of the group. An emergency response can be triggered, reported to higher-level institutions, and a linkage response on-site intervention mechanism of relevant departments can be triggered. The specific disposal process may include:

[0061] (1) Message notification

[0062] When the warning signal is generated or closed (the status is updated to false alarm closed, closed case, or pushed), the system will send a notice to the users involved in the warning signal (users with viewing permissions for this event in the bureau where the adverse reaction event of the warning signal is under the jurisdiction of which bureau will receive the notice). The warning signal involves medical institutions, the Health Commission, and the Food and Drug Administration.

[0063] (2) Warning disposal

[0064] For warning disposal, the preliminary follow-up unit is judged according to the granularity of the warning. If it is a single adverse reaction case warning generated by a monitoring point hospital and no manual card reporting is carried out, the preliminary follow-up units are the hospital and the district Health Commission. The hospital account can report and feedback (feedback to the district Health Commission and the Food and Drug Administration in the district) or close the false alarm.

[0065] If the hospital has carried out manual reporting, the preliminary follow-up units are only the district Health Commission, the district Food and Drug Administration, and medical institutions.

[0066] In other cases, when the warning granularity is less than the district level, the preliminary follow-up units are the district Health Commission, the district Food and Drug Administration, and medical institutions.

[0067] When the granularity is at the city level, the preliminary follow-up units are the city Health Commission, the city Food and Drug Administration, and medical institutions.

[0068] When a red alert is generated, it should be directly pushed as an event to the Municipal Health Commission, the Municipal Food and Drug Administration, and medical institutions.

[0069] (3) Storage judgment

[0070] Red alerts (individual alerts and group alerts) are directly pushed to the case library without judgment.

[0071] Orange, yellow, and blue (individual alerts and group alerts) need to be manually judged and then evaluated whether they need to be pushed to the case library.

[0072] An electronic device according to an embodiment of the present invention includes at least one memory; and a processor communicatively connected to the at least one memory; wherein, the memory stores instructions executable by the at least one processor, and the instructions are configured to execute the solution described in any of the above embodiments. Therefore, this electronic device has the same technical effects as any of the above embodiments, and will not be elaborated here.

[0073] The electronic devices of the embodiments of the present invention exist in various forms, including but not limited to:

[0074] (1) Mobile communication devices: The characteristics of such devices are that they have mobile communication functions and mainly aim to provide voice and data communication. Such terminals include: smart phones (such as iPhone), multimedia phones, functional phones, and low-end phones, etc.

[0075] (2) Ultra-mobile personal computer devices: Such devices belong to the category of personal computers, have computing and processing functions, and generally also have the characteristic of mobile Internet access. Such terminals include: PDA, MID, and UMPC devices, etc., such as iPad.

[0076] (3) Servers: Devices that provide computing services. The composition of a server includes a processor, a hard disk, a memory, a system bus, etc. Servers are similar to general computer architectures, but due to the need to provide highly reliable services, they have higher requirements in terms of processing power, stability, reliability, security, scalability, and manageability, etc.

[0077] (4) Other electronic devices with data interaction functions.

[0078] In addition, an embodiment of the present invention provides a computer-readable storage medium storing computer-executable instructions for executing the method flow described in any of the above embodiments.

[0079] It should be understood that the various forms of processes shown above can be used, with steps reordered, added or deleted. For example, the steps described in the present invention can be executed in parallel, sequentially or in different orders, as long as the desired results of the technical solutions disclosed in the present invention can be achieved, and no limitations are imposed herein.

[0080] The above specific embodiments do not constitute a limitation on the protection scope of the present invention. Those skilled in the art should understand that various modifications, combinations, sub - combinations and substitutions can be made according to design requirements and other factors. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention shall be included within the protection scope of the present invention.

Claims

1. A method for monitoring adverse drug reactions, characterized in that: The method comprises the following steps: S100, at the current monitoring time, obtain the monitoring information set D={D1, D2, ..., D i ,......,D n }, D i To set the monitoring information of the i-th monitored terminal in the geographical area, i ranges from 1 to n, and n is the number of monitored terminals; D i ={d i1 , d i2 ,......,d ij ,......,d ih（i） }, d ij is the monitoring information of the jth user of the i-th monitored terminal, where j ranges from 1 to h(i), and h(i) is the number of users of the i-th monitored terminal; d ij =(U ij , A ij ), U ij is the ID of the jth user of the ith monitored terminal; A ij For U ij The corresponding feature information, A ij =(M ij , L ij ), M ij For U ij Corresponding drug characteristic information, L ij For U ij Corresponding life characteristics information; M ij =(M 1 ij , M 2 ij , ..., M r ij , ..., M p ij ), M r ij M ij The rth drug feature in L, r ranges from 1 to p, and p is the number of drug features; ij =(L 1 ij , L 2 ij , ..., L s ij , ..., L q ij ), L s ij For L ij The sth life feature in the formula, s ranges from 1 to q, and q is the number of life features; the drug features at least include drug ID, drug origin, drug ingredients, and medication time; S200, for d ij , based on the preset adverse drug reaction benchmark table, judge d ij Is it adverse reaction data? If yes, please ij Stored in the adverse reaction information list corresponding to the currently set geographical area; the initial value of the adverse reaction information list corresponding to the currently set geographical area is a null value; S300, based on the adverse reaction information list corresponding to the currently set geographical area, obtain W target data sets; wherein the hth target data set C h ={C h1 , C h2 , ..., C hr , ..., C hg }, C hr C h The rth sub-dataset in C hr Meet the following conditions: C hr The drug ID, drug origin and drug ingredients corresponding to each data in are the same, and the corresponding medication time is the hth preset medication time, and the life characteristics corresponding to the corresponding life characteristic information are the preset rth life characteristic category; the value of h is 1 to W, the value of r is 1 to g, and g is the number of preset life characteristic categories; S400, acquiring a monitored terminal that needs an early warning based on an h-th target data set corresponding to a set geographical area within an h-th preset time period, and performing a corresponding early warning operation; the target data set corresponding to a set geographical area within each preset time period includes a target data set corresponding to a current set geographical area; In S400, the monitored end that needs to be warned is obtained based on at least a target data set corresponding to a set geographical area within a first preset time period and a second preset time period; wherein the duration of the second preset time period is greater than the duration of the first preset time period; S400 specifically includes: S410, obtaining a user quantity set G1={G11, G12, . . . , G11, G12, . . . , G12, G11, G12 ... r , ..., G1 g } and the user quantity set G2 corresponding to the target data set corresponding to the set geographical area within the second preset time period = {G21, G22, ..., G2 r , ..., G2 g }; G1 r is the number of users corresponding to the rth sub-dataset corresponding to the target data set corresponding to the set geographical area within the first preset time period, G2 r The number of users corresponding to the rth sub-data set corresponding to the target data set corresponding to the set geographical area within the second preset time period; S420, based on G1 r The first warning rule corresponding to the corresponding target data set determines whether it is necessary to perform a warning operation on the corresponding monitored end, and if necessary, performs the corresponding warning operation, and based on G2 r The second warning rule corresponding to the corresponding target data set determines whether it is necessary to perform a warning operation on the corresponding monitored end, and if necessary, performs the corresponding warning operation; Among them, each warning rule includes at least a trigger condition and a warning level; S420 specifically includes: If G1 r or G2 r If the corresponding trigger condition is met, it is determined that an early warning operation needs to be performed on the corresponding monitored end, and the corresponding early warning operation is performed based on the corresponding early warning level; the early warning level is represented by different colors, and the early warning operation corresponding to each early warning level is to mark the location of the corresponding monitored end with a corresponding color on the map corresponding to the set geographical area.

2. The method according to claim 1, characterized in that S200 specifically includes: S201, set the counting variable t=1; S202, obtain A ij With B t The similarity S between t ij ; if S t ij >S0, determine d ij is the adverse reaction data, and exits the current control program; otherwise, execute S203; B t is the t-th feature information in the preset adverse drug reaction benchmark table; S0 is the set similarity threshold; S203, set t = t + 1, if t ≤ m, execute S202, otherwise, determine d ij It is not adverse reaction data, and m is the number of characteristic information in the preset drug adverse reaction benchmark table.

3. The method according to claim 1, characterized in that The first preset time period is 1 day long, and the second preset time period is 3 days long.

4. The method according to claim 2, characterized in that: The similarity is cosine similarity.

5. A non-transitory computer-readable storage medium, wherein at least one instruction or at least one program is stored in the storage medium, characterized in that: The at least one instruction or the at least one program is loaded and executed by the processor to implement the method according to any one of claims 1 to 4.

6. An electronic device, characterized in that: The invention comprises a processor and the non-transitory computer-readable storage medium as claimed in claim 5.

Images